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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers in human population.
The 6-fluoro-3-formylchromone (FCC) has been shown to have anti-tumor activity against various tumor cells.
However, the effects of FCC on HCC cell lines have not yet been reported. This study aims to research the effects of
FCC on HCC and advance the understanding of the molecular mechanism.
Methods: HCC cell line SMMC-7721 was treated with FCC at various concentrations (0, 2, 5, 10, and 20 μg/ml) for
24, 48 and 72 h, respectively. The proliferations of SMMC-7721 cells were measured by MTT assays. After cultured
24 hours, cell cycle distribution and apoptosis were determined by flow cytometry. However, the expression levels
of PCNA, Bax and Bcl-2 were measured by western blotting after 48 hours.
Results: FCC displayed a dose- and time-dependent inhibition of the SMMC-7721 cell proliferations in vitro. It also
induced apoptosis with 45.4% and caused cell accumulation in G0/G1 phase with 21.5%. PCNA and Bcl-2 expression
was significantly suppressed by FCC in a dose-dependent manner (P < 0.05), while Bax expression was increased.
Conclusions: FCC could significantly inhibit HCC cell growth in vitro through cell cycle arrest and inducing
apoptosis by suppressing PCNA expression and modulating the Bax/Bcl-2 ratio.
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Background
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third common cause of cancer death in the
human population [1-4]. HCC is typically aggressive and
intrinsically resistant to conventional therapies such as
radiotherapy and chemotherapy [5-7]. Therefore, more ef-
fective therapeutic agents for treating HCC are desirable.
Previous studies have shown that chromone can in-
duce apoptosis of tumor cells and inhibit tumor growth
both in vitro and vivo [8,9]. The derivatives also showed
promising activity against various cancers such as pan-
creatic, prostate, breast, adenocarcinoma and non-small
cell lung carcinoma cancers. They can affect multiple
signaling pathways, such as NF-ĸB and PI3K/Akt path-
ways, which play important roles in mechanism of car-
cinogenesis [10-12].
In eukaryotic cells, PCNA plays a crucial role in DNA
replication, repair and cell proliferation in HCC [13].
This protein was involved in synthesis of lead- and lag-
DNA strands and provided an anchorage site [14]. Ap-
plied inhibitor to down-regulate PCNA expression may
cause the cell growth inhibition. Moreover, Bcl-2 family of
proteins showed the regulation function of mitochondrial-
mediated apoptosis [15]. In addition, Bcl-2 family are clas-
sified into two opposing subfamilies, and Bcl-2 and Bax
are the most representative members, respectively [16].
3-formylchrome, one of chromone derivatives, shows
significant tumor-specific cytotoxicity, dose-dependently
induced apoptosis in human oral squamous cell car-
cinoma cell line (HSC) and human promyelocytic
leukemia cell line (HL-60) [17]. It is also reported that
some 3-formylchromone derivatives represent more po-
tent cytotoxic activities against some tumor cells but low
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(FCC) was proved to be a modifier of multidrug resistance
in mouse lymphoma cells and in human Colo320 colon
cancer cells [18]. Moreover, Kawase et al. have confirmed
that FCC is one of the most cytotoxic 3-formylchromone
derivatives against tumor cell lines, such as HSC-2, HSC-3,
HL-60 and human submandibular gland carcinoma
cell line, through the experiments which described the
effects produced by 3-formaychromones replaced at the
C-6 position and evaluated the cytotoxicity against various
human cell lines [19]. Meanwhile, normal cells of human
gingival fibroblast (HGF), human pulp cell (HPC) and
human periodontal ligament fibroblast (HPLF) exhibit
a higher immunity to FCC as compared with the tumor
cell lines [19]. FCC is a promising approach for tumor
treatments. Nevertheless, to the best of our knowledge,
there is little report describing the effect of FCC on HCC
cell lines.
In the present study, the effect of FCC on proliferation
and apoptosis of HCC cell line SMMC-7721 were inves-
tigated. In addition, to further investigate the molecular
mechanisms of FCC on SMMC-7721 cells, we also stud-
ied the expression levels of proliferation marker PCNA
and the apoptosis related proteins Bax and Bcl-2 by
western blotting with FCC treatment.
Results
Effect of FCC on cell viability of SMMC-7721 cells
Chemical structure of FCC (MW= 192) was shown in
Figure 1A. The compound, is the derivative of 3-
formylchromone, formed when the hydrogen of the
sixth carbon atom have been replaced with fluorine. In
order to determine the effects of FCC on HCC, human
HCC cell line SMMC-7721 was treated by FCC with dif-
ferent doses for 24 h (Figure 1B). The proliferation of
SMMC-7721 cells was inhibited by FCC in a dose-
dependent manner. Further experiments showed that
FCC treatment inhibited the proliferation of SMMC-
7721 cells in a time-dependent manner (Figure 1B).
Effects of FCC on cell cycle and apoptosis of SMMC-7721
cells
The effect of FCC on cell cycle and apoptosis was ob-
served with flow cytometry. SMMC-7721 cells were
treated by FCC with various concentrations for 48 h.
SMMC-7721 cells exhibited increased cell percentages
in G0/G1 phase (Table 1) with an increase from 63.80%
to 85.30%. The percentages of apoptotic cells were sig-
nificantly increased in the treated group compared to
control group (p < 0.05) (Table 1) in a dose-dependent
manner. The apoptotic cells increased from a total of
2.8% to 48.2% for SMMC-7721 cells. Taken together,
FCC treatment could induce HCC cell apoptosis and
G0/G1 phase arrest.
Effects of FCC on PNCA, Bax and Bcl-2 expression
To further illustrate the molecular basis of the apoptosis
induction by FCC, we investigated the effect of FCC
on PCNA, Bax and Bcl-2 expression in SMMC. FCC
significantly suppressed PCNA expression in a dose-
dependent manner (Figure 2A and 2B). The total Bax
expression level was increased with FCC treatment in a
dose-dependent manner, while the total Bcl-2 expression
level was decreased, resulting in a higher Bax/Bcl-2 ratio
(Figure 2A and 2C).
Figure 1 FCC Inhibited Cell Proliferation of SMMC-7721 cells. (A) Chemical Structure of FCC. (B) Viability of SMMC-7721 cells treated with FCC. MTT
assay was performed to measure cell growth inhibition rate at 24 h, 48 h and 72 h after FCC treatment. Data shown were representatives of three experiments.
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Discussion
To our knowledge, this is the first report describing the
anti-tumor effect of FCC on HCC cell line SMMC-7721.
Our data demonstrated that FCC could inhibit the pro-
liferation of SMMC-7721 cells in vitro. It could down-
regulate PCNA and Bcl-2 expression and up-regulate
Bax expression. The results indicated that FCC could be
developed as a novel anti-tumor agent for treating HCC.
The imbalance between cell proliferation and death is
considered to be an important event in cancer progres-
sion [19,20]. Among the effects of anti-tumor reagents,
apoptosis and growth inhibition are the most common
responses on cancer cells [21,22]. In the present study,
we observed that the viability of SMMC-7721 cells could
be significantly decreased by FCC treatment for 24 h at
various concentrations (ranging from 2 to 20 μg/ml) ac-
cording to the MTT assay. The proliferation inhibition
effect of FCC on SMMC-7721 cells in vitro is consistent
with previous studies with other 3-formylchromone
derivatives [13-15]. It is suggested that the potential of
FCC treatment on the proliferation of human cancer cells
in vitro.
Cell cycle regulation is one of the most important bio-
processes. Traditionally, the cell cycle is divided into
four phases of G1-S-G2-M. DNA replication occurs dur-
ing S phase, and chromosome segregation occurs during
M phase. The S and M phases are separated by the so-
called gap phases, G1 (before DNA replication) and G2
(before mitosis) [23]. It has been generally accepted that
induction of cell cycle arrest and apoptosis are the im-
portant bio-reactions to anti-tumor reagents [24-26].
FCM cell cycle analysis in this study confirmed that FCC
could induce a cell cycle arrest in G0/G1 phase, even
the apoptosis when the damage couldn’t be repaired
on time. PCNA is a protein which is the compound
of cyclin D and cyclin-dependent kinases, involved in
the proliferation cells, and it is specifically expressed
in proliferating cell nuclei [27]. It has been shown
that the levels of PCNA expression are higher in cancer
tissues, including gastric, lung and breast cancer [28-30].
Several studies have emphasized the association of PCNA
with tumor malignancy grade and prognostic significance
in a number of malignancies [31,32]. Furthermore, it is
reported that non-steroidal anti-inflammatory drugs
(NSAIDs) could effectively postpone or hinder lung
carcinogenesis through down-regulating PCNA expres-
sion in rat model [33]. Our results demonstrated that FCC
could inhibit PCNA expression in SMMC-7721 cells with
a dose-dependent manner. Therefore, the proliferation in-
hibition in SMMC-7721 cells by FCC might be ascribed to
the suppressive effect on PCNA expression.
Members of the Bcl-2 family have been identified as
key regulators of apoptosis including two opposing sub-
families [34]. Bcl-2 proteins often form heterodimer
complexes with Bax proteins, which result in the release
of cytochrome c from the mitochondria and subsequent
induction of cell death [35]. Therefore, an increase in
the ratio of Bax/Bcl-2 is considered as one of the major
markers of pre-apoptosis. Several anti-tumor reagents
have been confirmed to inhibit tumor growth by influen-
cing the Bax/Bcl-2 ratio [36,37]. In the present study, our
results also suggest that FCC effectively induces apoptosis
in SMMC-7721 cells through up-regulation of the Bax/
Bcl-2 ratio.
Table 1 Effects of FCC on cell cycle and apoptosis of
SMMC-7721 cells
FCC (μg/mL) G0/G1 S G2/M Apoptosis (%)
0 63.8 ± 2.8 20.9 ± 3.8 15.3 ± 2.1 2.8 ± 1.3
2 69.1 ± 2.1 16.8 ± 2.4** 14.1 ± 1.8 9.5 ± 1.1**
5 76.4 ± 3.1 13.2 ± 1.4** 10.4 ± 0.9* 22.4 ± 1.9**
10 80.2 ± 1.9 11.0 ± 3.0** 8.8 ± 1.7** 37.5 ± 2.1**
20 85.3 ± 2.2 8.6 ± 2.3** 6.1 ± 2.0** 48.2 ± 1.7**
Cell cycle analysis and apoptosis of SMMC-7721 following FCC treatment for
48 h by flow cytometry. *p < 0.05, **p < 0.01, compared with control.
Figure 2 Effects of FCC treatment on PCNA, Bax, and Bcl-2 expression. (A) SMMC-7721 cells were treated with FCC at doses of 0, 2, 5, 10
and 20 μg/ml for 48 h. The cell lysates were prepared and analyzed for PCNA, Bax and Bcl-2 expression by Western blot analysis. Equal loading
was confirmed by stripping immunoblots and reprobing for β-actin. Data shown were representatives of three experiments. (B) Statistical analysis
of PCNA quantification. (C) The ratio of Bax to Bcl-2 protein. *p < 0.05, **p < 0.01, compared with control.
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Taken together, our results suggested that FCC could
induce G0/G1 cell cycle arrest and apoptosis in SMMC-
7721 cells through suppressing PCNA expression and
increasing Bax/Bcl-2 ratio, which advances our under-
standing on the molecular mechanisms of FCC in hepa-
tocarcinoma management. However, the effects of FCC
on SMMC-7721 were not investigated in animal models.
More extensive research involving animal studies are
needed in the future.
Conclusions
FCC could significantly inhibit HCC cell growth in vitro
through cell cycle arrest and inducing apoptosis by sup-




Human HCC cell line SMMC-7721 was purchased from
Cell Bank, Chinese Academy of Sciences (Shanghai,
China). Cells were maintained in RPMI1640 medium
(Gibco, Grand Island, NY) supplemented with 10% hea-
tinactivated fetal bovine serum (Gibco, Grand Island,
NY) at 37°C in a humidified atmosphere containing 5%
CO2. In order to inhibit aminoxidase, aminoguanidine
was added into RPMI1640 medium at a final concentra-
tion of 1 mmol/L.
All studies have been approved by The Ethics Committee
of Changhai Hospital and performed in accordance with
the ethical standards.
Antibodies and reagents
Antibodies against PCNA, Bax and Bcl-2 were purchased
from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). FCC, trypsin and MTT were obtained from
sigma (Sigma, St. Louis, MO, USA). Cell Cycle Detection
Kit was purchased from Thermo (Thermo Fisher Scien-
tific Inc, NH, USA).
Cell viability assay
The effect of FCC on cell viability was measured by
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium-
bromide (MTT) assay. The cells were plated at a
density of 1 × 104 per well in 96-well plates overnight
and then treated by FCC with different concentrations
of cell solution (0, 2, 5, 10, and 20 μg/ml). After incuba-
tion for 24 h, 48 h and 72 h at 37°C in a humidified in-
cubator, MTT (5 mg/ml in phosphate buffered saline
(PBS)) was added to each well and incubated for 4 h;
then the medium was totally removed, 0.15 ml of buffered
DMSO was added to each well. The absorbance was
recorded on a microplate reader at the wavelength of
490 nm. The effect on cell proliferation was assessed
as the percent cell viability wherein vehicle-treated cells
were taken as 100% viable.
Cell cycle analysis
After FCC treatment, the DNA content and cell cycle
distribution of SMMC-7721 cells were determined by
flow cytometry. Cells plated at a density of 1 × 106 per
well in 6-well plates, treated with FCC and then har-
vested at 24 h. The cells were washed twice with PBS.
They were then fixed in cold 70% ethanol and stored at
4°C for 30 min. Then ethanol was removed and the cells
were resuspended in PBS. The fixed cells were then
washed with PBS, treated with RNase (100 mg/ml), and
stained with Propidium Iodide (PI, 50 mg/ml) in the
dark for 30 min at 37°C. Cell cycle was analyzed by flow
cytometry.
Western blot analysis
SMMC-7721 cells were treated with FCC (0, 2, 5, 10,
and 20 μg/ml) for 48 h in complete cell medium. After
48 h of treatment, cells were harvested and cell lysates
were prepared and stored at -80°C for later use. The pro-
tein content in the lysates was determined using a modi-
fied Lowry assay [38]. For Western blot analysis, 50 μg
of protein from each sample were subjected to separate
on a SDS-PAGE gel. After electrophoresis, proteins were
electroblotted to polyvinylidene difluoride (PVDF) mem-
branes, and subsequently incubated in blocking buffer
(5% nonfat dry milk) for 12 h at 4°C. The blots were
incubated with appropriate primary antibody, washed,
and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody. The blots were detected
with chemiluminescence.
Statistical analysis
All data represents at least three independent experi-
ments and results were shown as mean ± SD. Statistical
differences between two groups were determined by Stu-
dent’s t-test. A significant difference was considered as
p < 0.05.
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